Throughout the last three months, 7 analysts have evaluated Regenxbio (NASDAQ:RGNX), offering a diverse set of opinions from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Regenxbio, presenting an average target of $36.43, a high estimate of $52.00, and a low estimate of $18.00. Highlighting a 16.44% decrease, the current average has fallen from the previous average price target of $43.60.

Decoding Analyst Ratings: A Detailed Look

An in-depth analysis of recent analyst actions unveils how financial experts perceive Regenxbio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regenxbio's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Regenxbio analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Regenxbio

Financial Milestones: Regenxbio's Journey

Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.

Revenue Challenges: Regenxbio's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -16.31%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Regenxbio's net margin excels beyond industry benchmarks, reaching -246.3%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Regenxbio's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.35%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.95%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Regenxbio's debt-to-equity ratio is below the industry average. With a ratio of 0.28, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.